ArticleFrontiers in medicine2025
A proteoglycan-based topical treatment for hair greying:
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Hair greying (canities) is a common and impactful feature of hair aging, primarily driven by oxidative stress, mitochondrial dysfunction, and progressive impairment of melanocyte function. Reactive oxygen species disrupt key melanogenic pathways, including Wnt/β-catenin signaling and microphthalmia-associated transcription factor (MITF) activity. Given the central role of oxidative and inflammatory processes in pigment loss, antioxidant and melanocyte-stimulating strategies represent promising approaches to delay hair greying. Methods: The present study evaluated the Results: PP-PTKL significantly restored MITF expression in a dose-dependent manner in human melanocytes subjected to Wnt/β-catenin pathway inhibition, with increases of 43.1% at 1% and a 3.7-fold increase at 5%. The formulation exhibited strong synergistic antioxidant activity, with total antioxidant capacity nearly four times higher than the sum of its individual components. In addition, histamine release was significantly reduced in mast cells, while IL-1Ra and S100A8/9 levels were significantly decreased compared with placebo, indicating attenuation of inflammation-associated oxidative stress. Conclusion: PP-PTKL demonstrates combined pro-melanogenic, antioxidant, and anti-inflammatory activity
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.